shortage of tirzepatide The FDA has declared an end to the two-year tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes drug Mounjaro — meaning that far more people could FDA Lifts Tirzepatide Shortage, Impacting

The Mounjaro Savings Card expires on December 31, 2025, for patients with commercial insurance that covers Mounjaro and on June 30, 2025, for patients whose insurance doesnt cover Mounjaro

If youre in Perimenopause or Menopause phase The weight changes that come with declining oestrogen are hormonal

In the case of semaglutide and tirzepatide, this overlap could lead to: Stronger gastrointestinal side effects Excessive appetite suppression Increased risk of dehydration Greater metabolic stress on the body Another important factor is that there is limited clinical research studying the combined use of these medications

Chronic low back pain is one of the leading causes of disability worldwide, and obesity is a major risk factor for developing low back pain

FDA-approved substitutes may exist